Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Blood
Bob LöwenbergSwiss Group for Clinical Cancer Research Collaborative Group (SAKK)

Abstract

In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained one of the major therapeutic challenges, with more than 75% relapses after complete remission. The anti-CD33 immunotoxin conjugate gemtuzumab ozogamicin (GO) has shown antileukemic remission induction activity in patients with relapsed AML. Patients with AML or refractory anemia with excess blasts in first complete remission attained after intensive induction chemotherapy were randomized between 3 cycles of GO (6 mg/m(2) every 4 weeks) or no postremission therapy (control) to assess whether GO would improve outcome. The 2 treatment groups (113 patients receiving GO vs 119 control patients) were comparable with regard to age (60-78 years, median 67 years), performance status, and cytogenetics. A total of 110 of 113 received at least 1 cycle of GO, and 65 of 113 patients completed the 3 cycles. Premature discontinuation was mainly attributable to incomplete hematologic recovery or intercurrent relapse. Median time to recovery of platelets 50 x 10(9)/L and neutrophils 0.5 x 10(9)/L after GO was 14 days and 20 days. Nonhematologic toxicities were mild overall, but there was 1 toxic death caused by liver failure. There were no significant dif...Continue Reading

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ute HegenbartRainer Storb
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas BüchnerWolfgang Hiddemann
Mar 18, 2009·British Journal of Haematology·Alan K BurnettUNKNOWN United Kingdom National Cancer Research Institute Haematological Oncology Study Group
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group

❮ Previous
Next ❯

Citations

Sep 12, 2012·Investigational New Drugs·Tetsuya TanimotoMasahiro Kami
Jun 29, 2012·Pharmaceutical Research·Kedan Lin, Jay Tibbitts
Nov 24, 2011·Current Hematologic Malignancy Reports·Joseph G Jurcic
Jul 5, 2011·Current Oncology Reports·Jenna Vanliere CanzonieroIvana Gojo
Jul 14, 2012·International Journal of Hematology·Masamitsu Yanada, Tomoki Naoe
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Elihu Estey
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Aug 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U BrunnbergW E Berdel
Jan 20, 2011·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Oct 15, 2011·Cancer Research·David J FitzGeraldIra Pastan
Jan 18, 2011·Hematology·Selina M Luger
Mar 29, 2011·Cancer Cell International·Stephanie Clayton, Shaker A Mousa
Jun 12, 2013·Frontiers in Bioscience (Landmark Edition)·Andrew J CowanRoland B Walter
May 9, 2014·Blood Reviews·George S LaszloRoland B Walter
Aug 28, 2014·Current Opinion in Oncology·Sergio AmadoriAdriano Venditti
Nov 26, 2010·Expert Review of Hematology·Karen W L Yee, Armand Keating
Nov 14, 2013·Expert Review of Hematology·Alessandro IsidoriGiuseppe Visani
Nov 7, 2014·Expert Review of Hematology·Øystein BruserudHåkon Reikvam
Jan 6, 2012·Expert Opinion on Investigational Drugs·Felicetto Ferrara
May 29, 2014·Expert Opinion on Biological Therapy·Felicitas Thol, Richard F Schlenk
Aug 4, 2011·Expert Opinion on Biological Therapy·Marie-Luise Hütter, Richard F Schlenk
Nov 1, 2010·Expert Opinion on Drug Discovery·Nicholas C NicolaidesLuigi Grasso
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Dec 24, 2015·Frontiers in Oncology·Kristen Pettit, Olatoyosi Odenike
Dec 7, 2010·Best Practice & Research. Clinical Haematology·Richard M Stone
Feb 15, 2011·British Journal of Haematology·Daniel A PollyeaBruno C Medeiros
Dec 11, 2013·British Journal of Haematology·Robin E GasiorowskiDerek N J Hart
Oct 17, 2014·American Journal of Hematology·Elihu H Estey
Jun 1, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Debora CapelliAttilio Olivieri
Apr 22, 2015·Current Hematologic Malignancy Reports·Sarah A Buckley, Roland B Walter
Mar 26, 2013·Oncoimmunology·Sylvia SnauwaertTessa Kerre
Feb 19, 2011·Leukemia Research·Maciej Bogdan ManieckiHolger Jon Møller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.